Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective
Main Authors: | Efthymios Manolis, Alfredo García‐Arieta, Anders Lindahl, Evangelos Kotzagiorgis, Jobst Limberg, Øyvind Holte, Paulo Paixao, Carolien Versantvoort, Flora Musuamba Tshinanu, Kevin Blake, Michiel Van Den Heuvel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-05-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12906 |
Similar Items
-
Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework
by: Ine Skottheim Rusten, et al.
Published: (2021-11-01) -
Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
by: Salvatore D’Agate, et al.
Published: (2020-09-01) -
Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia
by: Pauline Thémans, et al.
Published: (2019-05-01) -
Simplified Dosing Regimens for Gentamicin in Neonatal Sepsis
by: S. D’Agate, et al.
Published: (2021-03-01) -
Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications
by: Ines Lenić, et al.
Published: (2019-09-01)